ARDELYX, INC.ARDXEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Ardelyx, Inc. is a commercial-stage biopharmaceutical firm developing and commercializing innovative therapies for gastrointestinal, cardiorenal and metabolic diseases with high unmet medical needs. Its lead product is approved in the US for irritable bowel syndrome with constipation, and it holds a robust pipeline of early and late-stage drug candidates.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| S.S. OR | 9.10% | 21.5M | ▼ -1.50pp | 2024-11-14 |
| BlackRock, Inc. | 7.20% | 16.8M | — | 2024-01-26 |
| The Vanguard Group | 5.61% | 13.0M | — | 2024-02-13 |
| STATE STREET CORPORATION | 5.11% | 39.7M | ▼ -2.26pp | 2024-07-10 |
| Millennium Management LLC | 0.00% | 6.3K | — | 2024-01-31 |
Insider Transactions
Net 90d: +$672.1K · buys $1.95M / sells $1.27MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-15 | RAAB MICHAEL | President & CEO | Option exercise | 20.8K | $0.99 | $20.6K |
| 2026-04-15 | RAAB MICHAEL | President & CEO | Sell (open market) | 41.7K | $6.29 | $262.0K |
| 2026-03-16 | RAAB MICHAEL | President & CEO | Option exercise | 20.8K | $0.99 | $20.6K |
| 2026-03-16 | RAAB MICHAEL | President & CEO | Sell (open market) | 41.7K | $5.84 | $243.3K |
| 2026-02-24 | RAAB MICHAEL | President & CEO | Option exercise | 20.8K | $0.99 | $20.6K |
| 2026-02-24 | RAAB MICHAEL | President & CEO | Sell (open market) | 41.7K | $6.25 | $260.6K |
| 2026-02-20 | MOTT DAVID M | Director | Buy (open market) | 333.3K | $5.84 | $1.95M |
| 2026-02-20 | Reilly Joseph James | See Remarks | Sell (open market) | 4.4K | $5.87 | $25.7K |
| 2026-02-20 | Reilly Joseph James | See Remarks | Sell (open market) | 602 | $5.71 | $3.4K |
| 2026-02-20 | Reilly Joseph James | See Remarks | Sell (open market) | 2 | $5.70 | $11 |
1–10 of 31
Page 1 / 4